EYEG Eyegate Pharmaceuticals Inc.

5.19
+0.07  (+1%)
Previous Close 5.12
Open 5.22
Price To Book 3.63
Market Cap 24,012,858
Shares 4,626,755
Volume 119,522
Short Ratio
Av. Daily Volume 96,282
Stock charts supplied by TradingView

NewsSee all news

  1. EyeGate Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study

    WALTHAM, MA / ACCESSWIRE / March 31, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of

  2. EyeGate Pharma Reports Full Year 2019 Financial Results and Provides Business Update

    WALTHAM, MA / ACCESSWIRE / March 4, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of

  3. EyeGate Announces Completion of $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    WALTHAM, MA / ACCESSWIRE / January 3, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of

  4. EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    WALTHAM, MA / ACCESSWIRE / December 31, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders

  5. EyeGate Pharma Receives $1.9 Million from Exercised Warrants

    WALTHAM, MA / ACCESSWIRE / December 17, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company") announced today that it has received approximately $1.9 million from the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data released February 5, 2018 - co-primary endpoints not met.
EGP-437
Ocular inflammation and pain post cataract surgery
Phase 3 data did not demonstrate non-inferiority - September 4, 2018.
EGP-437
Non-infectious anterior uveitis
PRK pivotal trial met primary endpoint - November 22, 2019.
Ocular Bandage Gel
Wound healing
Data from follow-on pilot trial due 1H 2020.
Ocular Bandage Gel eye drop
Dry eye disease

Latest News

  1. EyeGate Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study

    WALTHAM, MA / ACCESSWIRE / March 31, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of

  2. EyeGate Pharma Reports Full Year 2019 Financial Results and Provides Business Update

    WALTHAM, MA / ACCESSWIRE / March 4, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of

  3. EyeGate Announces Completion of $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    WALTHAM, MA / ACCESSWIRE / January 3, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of

  4. EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    WALTHAM, MA / ACCESSWIRE / December 31, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders

  5. EyeGate Pharma Receives $1.9 Million from Exercised Warrants

    WALTHAM, MA / ACCESSWIRE / December 17, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company") announced today that it has received approximately $1.9 million from the

  6. EyeGate Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study

    WALTHAM, MA / ACCESSWIRE / December 2, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders

  7. EyeGate Pharma Hits Primary Endpoint in PRK Pivotal Study

    WALTHAM, MA / ACCESSWIRE / November 22, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders

  8. EyeGate Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update

    WALTHAM, MA / ACCESSWIRE / November 7, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders

  9. EyeGate Pharma Enrolls First Patient in Follow-on PE Pilot Study

    WALTHAM, MA / ACCESSWIRE / October 9, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of

  10. EyeGate Pharma Completes Randomization in Pivotal Study

    WALTHAM, MA / ACCESSWIRE / October 9, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of

  11. EyeGate Enters Into Agreement for $1.9 Million Private Placement

    WALTHAM, MA / ACCESSWIRE / September 30, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage company focused on developing products for treating

  12. EyeGate Pharma Regains Nasdaq Listing Compliance

    WALTHAM, MA / ACCESSWIRE / September 23, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders

  13. EyeGate Pharma Reaches 75% Randomization of Patients in Pivotal Study

    WALTHAM, MA / ACCESSWIRE / September 16, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye,

  14. EyeGate Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference

    WALTHAM, MA / ACCESSWIRE / September 3, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye,

  15. EyeGate Pharma Announces Reverse Stock Split Effective August 30, 2019

    WALTHAM, MA / ACCESSWIRE / August 29, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced

  16. EyeGate Pharma Reaches 50% Randomization of Patients in Pivotal Study

    WALTHAM, MA / ACCESSWIRE / August 26, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced